Volatility Stories
Is Tekla Life (USA Stocks:HQL) low volatility a good sign for institutional investors?
 | over a week ago at Macroaxis By Vlad Skutelnik |
Volatility is the spice of investing, and for those eyeing Tekla Life Sciences (HQL), understanding its market dynamics is crucial. With a daily balance of power at 1.56, the stock shows a significant tilt towards bullish sentiment, suggesting that buyers currently have the upper hand. However, the accumulation distribution figure of 0.01 indicates a relatively flat trend in terms of capital flow, which might raise questions about the stock's underlying strength. Continue Reading...
- HQL Tekla Life Sciences
- Latest Is Tekla Life low volatility a good sign for institutional investors
- HQL 12.61 0.01
- Low 12.55
- High 12.72
- Alpha -0.0183
- Beta 0.81
- Return On Equity 0.0128
- Return On Asset -0.0032
- Operating Margin (1.01) %
- Current Valuation 364.08 M
- Shares Outstanding 28.87 M
- Shares Owned By Institutions 30.71 %
- Number Of Shares Shorted 51.89 K
- Price To Earning 2.84 X
- Price To Book 0.92 X
- Price To Sales 111.12 X
- Revenue 86.69 M
- Gross Profit 3.28 M
- EBITDA 22.35 M
- Net Income 85.3 M
- Cash And Equivalents 292.4 K
- Cash Per Share 0.01 X
- Total Debt 888.61 K
- Debt To Equity 0.02 %
- Current Ratio 1.34 X
- Book Value Per Share 13.71 X
- Cash Flow From Operations (12.8 M)
- Short Ratio 0.35 X
- Earnings Per Share (0.48) X
- Beta 0.68
- Market Capitalization 364.08 M
- Total Asset 460.58 M
- Retained Earnings 44.13 M
- Annual Yield 0.15 %
- Five Year Return 8.83 %
- Net Asset 460.58 M
- Last Dividend Paid 1.94
- Accumulation Distribution 0.0134
- Daily Balance Of Power 0.0588
- Rate Of Daily Change 1.0
- Day Median Price 12.64
- Day Typical Price 12.63
- Market Facilitation Index 0.17
- Price Action Indicator (0.02)
- Period Momentum Indicator 0.01
- Relative Strength Index 65.59
Macroaxis uses a strict editorial review process to publish stories and blog posts. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
Every rose has its thorn, and Foot Locker's stock is no exception when it comes to volatility. With a Market Facilitation Index of 0.18, the stock's price movements can be quite unpredictable, making it a rollercoaster ride for investors. Despite the turbulence, the analyst consensus leans towards a buy, suggesting potential growth opportunities.
| over three weeks ago at Macroaxis By Raphi Shpitalnik |  |
Collplant Biotechnologies has $3.08 million in liabilities and a Debt to Equity (D/E) ratio of 0.08, indicating a conservative approach to borrowing. With a current ratio of 15.89, the company is well-positioned to meet its short-term financial obligations. It's important to assess Collplant's debt in conjunction with its cash reserves and equity to get a complete picture of its financial health.
Main Points
Collplant Biotechnologies, trading at a last price of 1.93, presents a potential buying opportunity for those who can stomach its volatility, as evidenced by a standard deviation of 4.3. However, with a maximum drawdown of 20.39, investors should carefully weigh the risks before diving in.| over three weeks ago at Macroaxis By Vlad Skutelnik | |
Crypto day trading is not about luck. It relies on strategic thinking, discipline, and continuous learning. The 24/7 nature of cryptocurrency markets introduces unique trading rhythms, very different from traditional exchanges. Assets like Bitcoin and Ethereum tend to follow patterns influenced by technical indicators, trading volume, and favorable bid-ask spreads.
| over a month ago at Macroaxis By Aina Ster |  |
Ensysce Biosciences presents an intriguing opportunity for investors willing to navigate its recent volatility, with a standard deviation of 13.55 indicating significant price fluctuations. Despite a recent price change of -0.28, the company's innovative approach to addressing opioid misuse through its Trypsin Activated Abuse Protection platform could offer strategic long-term potential.
Important Takeaways
Ensysce Biosciences has approximately $3.15 million in cash and a positive cash flow from operations of $7.5 million, resulting in a cash-per-share (CPS) ratio of 0.1. The company's Beta is 1.37, indicating higher volatility compared to the market.| over a month ago at Macroaxis By Gabriel Shpitalnik |  |
Strike while the iron is hot might be the best advice for those eyeing Generac Holdings' stock. With its current volatility, GNRC is offering intriguing opportunities for investors willing to navigate the ups and downs. The stock's real value is pegged at $139.17, while its market value sits at $112.89, suggesting potential undervaluation.
| over a month ago at Macroaxis By Raphi Shpitalnik | |
Sports organizations pour unimaginable amounts of money into their most valuable assets—stadiums, player contracts, and youth programs—while sportsbooks invest in things like bet insurance bonuses. Losses sting, and the risks are huge. This essay explores how digital tools like blockchain and AI could tighten that safety net, blending insurance and investment into something sharper. Blockchain could track funds with ironclad clarity, while AI might predict where injuries or performance drops could hit hardest. It’s a timely look at how tech could stabilize cash flow and growth, urging stakeholders to see these tools as a modern shield for sports’ financial future—beyond old-school policies and seasonal swings.
| over a month ago at Macroaxis By Aina Ster | |
Tesla Inc currently has about $16.25 billion in cash and generates $14.92 billion in positive cash flow from operations, resulting in a cash-per-share ratio of 6.68. The stock's beta is -0.55, suggesting it could offer diversification benefits in a portfolio. This means that as market returns rise, Tesla's returns might decrease, but at a slower pace.
| over a month ago at Macroaxis By Vlad Skutelnik | |
Raytheon Technologies Corp, a key player in the Aerospace & Defense industry, presents an intriguing opportunity for investors willing to embrace some volatility. With a Coefficient of Variation of 1.4K, the stock exhibits a moderate level of risk, which could be appealing for those looking to capitalize on potential price movements. Additionally, the Jensen Alpha of 0.24 suggests that the stock has been performing slightly better than expected, offering a potential edge for long-term investors.
Key Takeaways
Raytheon Technologies Corp holds about $6.22 billion in cash and generates $7.16 billion in positive cash flow from its operations. This translates to a cash-per-share (CPS) ratio of 3.66.| over a month ago at Macroaxis By Aina Ster | |
All that glitters is not gold, but for investors eyeing Gold Resource Corporation, the recent signs of stabilizing volatility might just be the golden opportunity they've been waiting for. After a period of tumultuous price swings, the stock's daily balance of power has settled at -1.0, suggesting a potential shift in market sentiment. With the analyst consensus leaning towards a strong buy, the current landscape presents a compelling case for those looking to capitalize on the evolving dynamics within the metals and mining sector.
| over two months ago at Macroaxis By Ellen Johnson |  |